Bayer and Orion Expand Clinical Development Program for BAY-1841788 (ODM-201) in Prostate Cancer

Phase III study to be initiated in metastatic hormone-sensitive prostate cancer assessing the androgen-receptor antagonist in combination with standard androgen deprivation therapy and the chemotherapy docetaxel Start of patient enrollment expected towa... Biopharmaceuticals, OncologyBayer, Orion Corp, prostate cancer, ARASENS
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news